Development of targeted therapies for Parkinson's disease and related synucleinopathies

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 1996-2003

  Sybertz, Edmund ^a   Krainc, Dimitri ^b  

^a Lysosomal Therapeutics Inc   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Glucocerebrosidase; Glycosphingolipids; Lysosomes

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; AFEGOSTAT; ALPHA SYNUCLEIN; AMBROXOL; BETA N ACETYLHEXOSAMINIDASE; CCG 203586; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; COMPOUND 40; ELIGLUSTAT; ENZYME ACTIVATOR; GANGLIOSIDE GM2; GBA1 ENZYME; GBA2 ENZYME; GENZ 529468; GLUCOSYLCERAMIDASE; GLYCOLIPID; GZ 161; MIGLUSTAT; N (5' ADAMANTAN 1' YL METHOXY) PHENYL 1 DEOXYNORJIRIMYCIN; PYRIMETHAMINE; RECOMBINANT ENZYME; RECOMBINANT GLUCOCEREBROSIDASE; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; ENCEPHALITIS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; GAUCHER DISEASE; HUMAN; INTRACELLULAR TRANSPORT; LIPID METABOLISM; LYSOSOME; MOLECULARLY TARGETED THERAPY; NEUROPROTECTION; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN PROTEIN INTERACTION; REVIEW; SANDHOFF DISEASE; SURVIVAL; SYNUCLEINOPATHY; TAY SACHS DISEASE; ADOLESCENT; ADULT; CHILD; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ALPHA-SYNUCLEIN; CHILD; CHILD, PRESCHOOL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLYCOLIPIDS; HUMANS; LIPID METABOLISM; MUTATION; PARKINSON DISEASE;

EID: 84907486116     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R047381     Document Type: Review

References (79)

1. Levine, B., and G. Kroemer. 2008. Autophagy in the pathogenesis of disease. Cell. 132: 27-42.
2. Krainc, D. 2010. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch. Neurol. 67: 388-392.
3. Yamamoto, A., J. J. Lucas, and R. Hen. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101: 57-66.
4. Zu, T., L. A. Duvick, M. D. Kaytor, M. S. Berlinger, H. Y. Zoghbi, H. B. Clark, and H. T. Orr. 2004. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24: 8853-8861.
5. Lim, Y., V. M. Kehm, E. B. Lee, J. H. Soper, C. Li, J. Q. Trojanowski, and V. M. Lee. 2011. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 31: 10076-10087.
6. Devine, M. J., K. Gwinn, A. Singleton, and J. Hardy. 2011. Parkinson's disease and α-synuclein expression. Mov. Disord. 26: 2160-2168.
7. Bellettato, C. M., and M. Scarpa. 2010. Pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 33: 347-362.
8. Shachar, T., C. Lo Bianco, A. Recchia, C. Wiessner, A. Raas-Rothschild, and A. H. Futerman. 2011. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26: 1593-1604.
9. Sack, G. H., Jr. 1980. Clinical diversity in Gaucher's disease. Johns Hopkins Med. J. 146: 166-170.
10. Sidransky, E. 2005. Gaucher disease and parkinsonism. Mol. Genet. Metab. 84: 302-304.
11. Neudorfer, O., N. Giladi, D. Elstein, A. Abrahamov, T. Turezkite, E. Aghai, A. Reches, B. Bembi, and A. Zimran. 1996. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 89: 691-694.
12. Tayebi, N., J. Walker, B. Stubblefield, E. Orvisky, M. E. LaMarca, K. Wong, H. Rosenbaum, R. Schiffmann, B. Bembi, and E. Sidransky. 2003. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79: 104-109.
13. Goker-Alpan, O., R. Schiffmann, M. E. LaMarca, R. L. Nussbaum, A. McInerney-Leo, and E. Sidransky. 2004. Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41: 937-940.
14. Goker-Alpan, O., B. K. Stubblefield, B. I. Giasson, and E. Sidransky. 2010. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120: 641-649.
15. Wong, K., E. Sidransky, A. Verma, T. Mixon, G. D. Sandberg, L. K. Wakefield, A. Morrison, A. Lwin, C. Colegial, J. M. Allman, et al. 2004. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82: 192-207.
16. Sidransky, E., M. A. Nalls, J. O. Aasly, J. Aharon-Peretz, G. Annesi, E. R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, et al. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361: 1651-1661.
17. Mazzulli, J. R., Y. H. Xu, Y. Sun, A. L. Knight, P. J. McLean, G. A. Caldwell, E. Sidransky, G. A. Grabowski, and D. Krainc. 2011. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 146: 37-52.
18. Gegg, M. E., D. Burke, S. J. Heales, J. M. Cooper, J. Hardy, N. W. Wood, and A. H. Schapira. 2012. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72: 455-463.
19. Yap, T. L., A. Velayati, E. Sidransky, and J. C. Lee. 2013. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 108: 56-64.
20. Cullen, V., S. P. Sardi, J. Ng, Y. H. Xu, Y. Sun, J. J. Tomlinson, P. Kolodziej, I. Kahn, P. Saftig, J. Woulfe, et al. 2011. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69: 940-953.
21. Lukina, E., N. Watman, E. A. Arreguin, M. Banikazemi, M. Dragosky, M. Iastrebner, H. Rosenbaum, M. Phillips, G. M. Pastores, D. I. Rosenthal, et al. 2010. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type. Blood. 116: 893-899.
22. Lukina, E., N. Watman, E. A. Arreguin, M. Dragosky, M. Iastrebner, H. Rosenbaum, M. Phillips, G. M. Pastores, R. S. Kamath, D. I. Rosenthal, et al. 2010. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 116: 4095-4098.
23. Shayman, J. A. 2010. Eliglustat tartrate: glucosylceramide synthase inhibitor for the treatment of type 1 Gaucher disease. Drugs Future. 35: 613-620.
24. Nietupski, J. B., J. J. Pacheco, W. L. Chuang, K. Maratea, L. Li, J. Foley, K. M. Ashe, C. G. Cooper, J. M. Aerts, D. P. Copeland, et al. 2012. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol. Genet. Metab. 105: 621-628.
25. Elstein, D., C. Hollak, J. M. Aerts, S. van Weely, M. Maas, T. M. Cox, R. H. Lachmann, M. Hrebicek, F. M. Platt, T. D. Butters, et al. 2004. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type 1 Gaucher disease. J. Inherit. Metab. Dis. 27: 757-766.
26. Treiber, A., O. Morand, and M. Clozel. 2007. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 37: 298-314.
27. Cox, T., R. Lachmann, C. Hollak, J. Aerts, S. van Weely, M. Hrebícek, F. Platt, T. Butters, R. Dwek, C. Moyses, et al. 2000. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355: 1481-1485.
28. Schiffmann, R., E. J. Fitzgibbon, C. Harris, C. DeVile, E. H. Davies, L. Abel, I. N. van Schaik, W. Benko, M. Timmons, M. Ries, et al. 2008. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann. Neurol. 64: 514-522.
29. Larsen, S. D., M. W. Wilson, A. Abe, L. Shu, C. H. George, P. Kirchhoff, H. D. Showalter, J. Xiang, R. F. Keep, and J. A. Shayman. 2012. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J. Lipid Res. 53: 282-291.
30. Arthur, J. R., M. W. Wilson, S. D. Larsen, H. E. Rockwell, J. A. Shayman, and T. N. Seyfried. 2013. Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem. Res. 38: 866-875.
31. Cabrera-Salazar, M. A., M. Deriso, S. D. Bercury, L. Li, J. T. Lydon, W. Weber, N. Pande, M. A. Cromwell, D. Copeland, J. Leonard, et al. 2012. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE. 7: e43310.
32. Richter, F., S. M. Fleming, M. Watson, V. Lemesre, L. Pelligrino, B. Ranes, C. Zhu, F. Montazavi, C. K. Mulligan, P. C. Sioshansi, et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics. Epub ahead of print. July 20, 2014.
33. Sardi, S. P., J. Clarke, C. Viel, M. Chan, T. J. Tamsett, C. M. Treleaven, J. Bu, L. Sweet, M. A. Passini, J. C. Dodge, et al. 2013. Augmenting CNS glucocerebrosidase as a therapeutic strategy for Parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. USA. 110: 3537-3542.
34. Sardi, S. P., J. Clarke, C. Kinnecom, T. J. Tamsett, L. Li, L. M. Stanek, M. A. Passini, G. A. Grabowski, M. G. Schlossmacher, R. L. Sidman, et al. 2011. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl. Acad. Sci. USA. 108: 12101-12106.
35. Ridley, C. M., K. E. Thur, J. Shanahan, N. B. Thillaiappan, A. Shen, K. Uhl, C. M. Walden, A. A. Rahim, S. N. Waddington, F. M. Platt, et al. 2013. β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J. Biol. Chem. 288: 26052-26066.
36. Abian, O., P. Alfonso, A. Velazquez-Campoy, P. Giraldo, M. Pocovi, and J. Sancho. 2011. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol. Pharm. 8: 2390-2397.
37. Alfonso, P., S. Pampín, J. Estrada, J. C. Rodríguez-Rey, P. Giraldo, J. Sancho, and M. Pocoví. 2005. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol. Dis. 35: 268-276.
38. Boomkamp, S. D., and T. D. Butters. 2008. Glycosphingolipid disorders of the brain. Subcell. Biochem. 49: 441-467.
39. Mukherjee, S., and F. R. Maxfield. 2004. Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta. 1685: 28-37.
40. Kluenemann, H. H., J. G. Nutt, M. Y. Davis, and T. D. Bird. 2013. Parkinsonism syndrome in heterozygotes for Niemann-Pick C1. J. Neurol. Sci. 335: 219-220.
41. Davidson, C. D., N. F. Ali, M. C. Micsenyi, G. Stephney, S. Renault, K. Dobrenis, D. S. Ory, M. T. Vanier, and S. U. Walkley. 2009. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE. 4: e6951.
42. Stein, V. M., A. Crooks, W. Ding, M. Prociuk, P. O'Donnell, C. Bryan, T. Sikora, J. Dingemanse, M. T. Vanier, S. U. Walkley, et al. 2012. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J. Neuropathol. Exp. Neurol. 71: 434-448.
43. Fan, M., R. Sidhu, H. Fujiwara, B. Tortelli, J. Zhang, C. Davidson, S. U. Walkley, J. H. Bagel, C. Vite, N. M. Yanjanin, et al. 2013. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J. Lipid Res. 54: 2800-2814.
44. Chien, Y. H., N. C. Lee, L. K. Tsai, A. C. Huang, S. F. Peng, S. J. Chen, and W. L. Hwu. 2007. Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J. Inherit. Metab. Dis. 30: 826.
45. Patterson, M. C., D. Vecchio, H. Prady, L. Abel, and J. E. Wraith. 2007. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 6: 765-772.
46. Chien, Y. H., S. F. Peng, C. C. Yang, N. C. Lee, L. K. Tsai, A. C. Huang, S. C. Su, C. C. Tseng, and W. L. Hwu. 2013. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J. Inherit. Metab. Dis. 36: 129-137.
47. Wennekes, T., R. J. van den Berg, W. Donker, G. A. van der Marel, A. Strijland, J. M. Aerts, and H. S. Overkleeft. 2007. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J. Org. Chem. 72: 1088-1097.
48. Ashe, K. M., D. Bangari, L. Li, M. A. Cabrera-Salazar, S. D. Bercury, J. B. Nietupski, C. G. Cooper, J. M. Aerts, E. R. Lee, D. P. Copeland, et al. 2011. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS ONE. 6: e21758.
49. Fantini, J., and N. Yahi. 2011. Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: key role of tyrosine 39 in membrane insertion. J. Mol. Biol. 408: 654-669.
50. Martinez, Z., M. Zhu, S. Han, and A. L. Fink. 2007. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry. 46: 1868-1877.
51. Jeyakumar, M., T. D. Butters, M. Cortina-Borja, V. Hunnam, R. L. Proia, V. H. Perry, R. A. Dwek, and F. M. Platt. 1999. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA. 96: 6388-6393.
52. Platt, F. M., G. R. Neises, G. Reinkensmeier, M. J. Townsend, V. H. Perry, R. L. Proia, B. Winchester, R. A. Dwek, and T. D. Butters. 1997. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276: 428-431.
53. Platt, F. M., M. Jeyakumar, U. Andersson, T. Heare, R. A. Dwek, and T. D. Butters. 2003. Substrate reduction therapy in mouse models of glycosphingolipidosis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358: 947-954.
54. Wortmann, S. B., D. J. Lefeber, G. Dekomien, M. A. Willemsen, R. A. Wevers, and E. Morava. 2009. Substrate deprivation therapy in juvenile Sandhoff disease. J. Inherit. Metab. Dis. 32(Suppl 1): S307-S311.
55. Masciullo, M., M. Santoro, A. Modoni, E. Ricci, J. Guitton, P. Tonali, and G. Silvestri. 2010. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J. Inherit. Metab. Dis. 33(Suppl 3): S355-S361.
56. Shapiro, B. E., G. M. Pastores, J. Gianutsos, C. Luzy, and E. H. Kolodny. 2009. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet. Med. 11: 425-433.
57. Wu, G., Z. H. Lu, N. Kulkarni, and R. W. Ledeen. 2012. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J. Neurosci. Res. 90: 1997-2008.
58. Schneider, J. S., S. M. Gollomp, S. Sendek, A. Colcher, F. Cambi, and W. Du. 2013. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 324: 140-148.
59. Wei, J., M. Fujita, M. Nakai, M. Waragai, A. Sekigawa, S. Sugama, T. Takenouchi, E. Masliah, and M. Hashimoto. 2009. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am. J. Pathol. 174: 1891-1909.
60. Wei, J., M. Fujita, A. Sekigawa, K. Sekiyama, M. Waragai, and M. Hashimoto. 2009. Gangliosides' protection against lysosomal pathology of synucleinopathies. Autophagy. 5: 860-861.
61. Steet, R. A., S. Chung, B. Wustman, A. Powe, H. Do, and S. A. Kornfeld. 2006. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. USA. 103: 13813-13818.
62. Steet, R., S. Chung, W. S. Lee, C. W. Pine, H. Do, and S. Kornfeld. 2007. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem. Pharmacol. 73: 1376-1383.
63. Kornhaber, G. J., M. B. Tropak, G. H. Maegawa, S. J. Tuske, S. J. Coales, D. J. Mahuran, and Y. Hamuro. 2008. Isofagomine induced stabilization of glucocerebrosidase. ChemBioChem. 9: 2643-2649.
64. Lieberman, R. L., J. A. D'aquino, D. Ringe, and G. A. Petsko. 2009. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 48: 4816-4827.
65. Khanna, R., E. R. Benjamin, L. Pellegrino, A. Schilling, B. A. Rigat, R. Soska, H. Nafar, B. E. Ranes, J. Feng, Y. Lun, et al. 2010. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J. 277: 1618-1638.
66. Sun, Y., B. Liou, Y. H. Xu, B. Quinn, W. Zhang, R. Hamler, K. D. Setchell, and G. A. Grabowski. 2012. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem. 287: 4275-4287.
67. Sun, Y., H. Ran, B. Liou, B. Quinn, M. Zamzow, W. Zhang, J. Bielawski, K. Kitatani, K. D. Setchell, Y. A. Hannun, et al. 2011. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS ONE. 6: e19037.
68. Maegawa, G. H., M. B. Tropak, J. D. Buttner, B. A. Rigat, M. Fuller, D. Pandit, L. Tang, G. J. Kornhaber, Y. Hamuro, J. T. Clarke, et al. 2009. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284: 23502-23516.
69. Bendikov-Bar, I., I. Ron, M. Filocamo, and M. Horowitz. 2011. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol. Dis. 46: 4-10.
70. Bendikov-Bar, I., G. Maor, M. Filocamo, and M. Horowitz. 2013. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50: 141-145.
71. Suzuki, T., M. Shimoda, K. Ito, S. Hanai, H. Aizawa, T. Kato, K. Kawasaki, T. Yamaguchi, H. D. Ryoo, N. Goto-Inoue, et al. 2013. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS ONE. 8: e69147.
72. Zimran, A., G. Altarescu, and D. Elstein. 2013. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50: 134-137.
73. Goldin, E., W. Zheng, O. Motabar, N. Southall, J. H. Choi, J. Marugan, C. P. Austin, and E. Sidransky. 2012. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS ONE. 7: e29861.
74. Patnaik, S., W. Zheng, J. H. Choi, O. Motabar, N. Southall, W. Westbroek, W. A. Lea, A. Velayati, E. Goldin, E. Sidransky, et al. 2012. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55: 5734-5748.
75. Maegawa, G. H., M. Tropak, J. Buttner, T. Stockley, F. Kok, J. T. Clarke, and D. J. Mahuran. 2007. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 282: 9150-9161.
76. Osher, E., A. Fattal-Valevski, L. Sagie, N. Urshanski, Y. Amir-Levi, S. Katzburg, L. Peleg, T. Lerman-Sagie, A. Zimran, D. Elstein, et al. 2011. Pyrimethamine increases β-hexosaminidase A activity in patients with late onset Tay Sachs. Mol. Genet. Metab. 102: 356-363.
77. Clarke, J. T., D. J. Mahuran, S. Sathe, E. H. Kolodny, B. A. Rigat, J. A. Raiman, and M. B. Tropak. 2011. An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol. Genet. Metab. 102: 6-12.
78. Tropak, M. B., J. E. Blanchard, S. G. Withers, E. D. Brown, and D. Mahuran. 2007. High-throughput screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol. 14: 153-164.
79. Rountree, J. S., T. D. Butters, M. R. Wormald, S. D. Boomkamp, R. A. Dwek, N. Asano, K. Ikeda, E. L. Evinson, R. J. Nash, and G. W. Fleet. 2009. Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease. ChemMedChem. 4: 378-392.